AtriCure, Inc. reported 2026 quarter results with revenue of $153.6M, up 12.8% from $136.14M a year earlier, and diluted EPS of $0.18 compared with ($0.13) in the prior-year quarter as the company returned to net income of $8.96M versus a loss of ($6.19M).Financial Highlights¹ Reported as “Revenue”…
ATRC (AtriCure, Inc.) is set to announce its Q2'26 results on July 23, after the market closes. The earnings are expected to be disclosed at 4:01 PM ET (8:01 PM UTC).For Q2'26, revenue estimate is 151.84 million USD with EPS (earnings per share) anticipated at (0.00) USD. Learn more details at ATRC…
MASON, Ohio--(BUSINESS WIRE)--July 02, 2026--AtriCure, Inc. NASDAQ:ATRC, a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026…
